GET THE APP
Predictive Biomarker Impact Factor | Open Access Journals
Bioceramics Development and Applications

Bioceramics Development and Applications

ISSN: 2090-5025

Open Access
Spanish Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil
Submit Manuscript arrow_forward arrow_forward ..

Predictive Biomarker Impact Factor

 

Impact Factor is an indicator of the number of citations within scientific journals of clinical and medical category. The impact factor is measured based on the frequency with which the articles of a journal are cited in scientific publications, it is a supposed marker of the quality of the journal. Journal publication, investigator index, and journal impact factors are used to measure the impact and importance of the research. The journal impact factor is the metric most used to measure the quality of the clinical journal. Immunomodulatory drugs (IMiD) are very active in the treatment of hematologic malignancies, such as multiple myeloma (MM), non-Hodgkin lymphoma, and chronic lymphocytic leukemia, but the mechanisms of action are not yet fully understood. Although several mechanisms have been proposed to explain the activity of these drugs in multiple myeloma (MM), the precise cellular targets and molecular mechanisms have only been recently clarified. Cereblon (CRBN), a member of the cullin 4-ring ligase complex (CRL4), has been identified as the primary target of thalidomide teratogenicity and, furthermore, as an essential requirement for response to IMiD therapy. Cereblon's central role as a target for lenalidomide and pomalidomide suggests potential utility as a predictive biomarker of response or resistance to IMiD therapy; Low CRBN expression was found to correlate with poor drug response in MM and primary MM cell lines. Expression of the CRBN protein in myeloma cells evaluated by immunohistochemistry is a practical approach to predict the IMiD response in MM patients. Therefore, CRBN expression is a potential predictive biomarker for response and survival in MM, decreasing the resistance developed by expression to IMiD. The discovery of the cereblon as a target for thalidomide and IMiDs has led to a better understanding of the mechanism of molecular action by these agents. At the same time, there is significant clinical interest in investigating the possible role of cerebelle as a biomarker for the response or resistance of IMiD compounds. (Adel Gouri, AmelBouacha, AouliaDekaken, FaizaMehiddine, Ahmed AimenBentorki, AminaYakhlef and Mehdi Beleilli, Cereblon as predictive biomarker for sensitivity to Imid therapy)

High Impact List of Articles
Conference Proceedings

Relevant Topics in Science & Technology

Awards & Nominations

50+ Million Readerbase

Journal Highlights

Google Scholar citation report
Citations: 1050

Bioceramics Development and Applications received 1050 citations as per Google Scholar report

Citation image

Indexed In

Related Links

 

Open Access Journals

arrow_upward arrow_upward